

Tegsedi[®] (inotersen) (Subcutaneous)

Document Number: IC-0401

Last Review Date: 08/01/2024

Date of Origin: 10/30/2018

Dates Reviewed: 10/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 08/2024

I. Length of Authorization

Initial coverage will be provided for 6 months and may be renewed annually thereafter.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Tegsedi 284 mg/1.5 mL single-dose prefilled syringe: 1 prefilled syringe every 7 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- 284 mg every 7 days

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient has a platelet count of $\geq 100 \times 10^9/L$; **AND**
- Patient has a baseline urine protein to creatinine ratio (UPCR) of $< 1000 \text{ mg/g}$ and UPCR will be monitored every 2 weeks during treatment; **AND**
- Both the patient **AND** prescriber are enrolled in and meet the conditions of the Tegsedi REMS program; **AND**
- Patient is receiving supplementation with vitamin A at the recommended daily allowance; **AND**
- Must not be used in combination with other transthyretin (TTR) reducing or stabilizing agents (e.g., patisiran, tafamidis, vutrisiran, etc.); **AND**

Polyneuropathy due to Hereditary Transthyretin-Mediated (hATTR) Amyloidosis † Φ ^{1,5,6}

- Patient has a definitive diagnosis of hATTR amyloidosis as documented in a proband with suggestive findings (including imaging or histopathology findings of amyloidosis) and a

heterozygous pathogenic (or likely pathogenic) variant in *TTR* identified by molecular genetic testing; **AND**

- Used for the treatment of polyneuropathy as demonstrated by at least TWO of the following criteria:
 - Subjective patient symptoms are suggestive of neuropathy
 - Abnormal nerve conduction studies are consistent with polyneuropathy
 - Abnormal neurological examination is suggestive of neuropathy; **AND**
 - Patient's peripheral neuropathy is attributed to hATTR and other causes of neuropathy have been excluded; **AND**
 - Baseline in strength/weakness has been documented using an objective clinical measuring tool (e.g., Medical Research Council (MRC) muscle strength, etc.); **AND**
 - Patient has not been the recipient of an orthotopic liver transplant (OLT)
- † FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria ^{1,5,6}

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and indication specific criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: stroke and cervicocephalic arterial dissection, ocular symptoms related to vitamin A deficiency (e.g., night blindness), severe thrombocytopenia, glomerulonephritis and renal toxicity, liver injury, serious inflammatory and immune adverse reactions, hypersensitivity reactions/antibody formation, etc.; **AND**
- Disease response compared to pre-treatment baseline as evidenced by stabilization or improvement in one or more of the following:
 - Signs and symptoms of neuropathy
 - MRC muscle strength

V. Dosage/Administration ¹

Indication	Dose
hATTR polyneuropathy	<p>The recommended dose of Tegsedi is 284 mg injected subcutaneously once weekly.</p> <ul style="list-style-type: none">• For consistency of dosing, patients should be instructed to give the injection on the same day every week.• If a dose is missed, patients should be instructed to take the missed dose as soon as possible, unless the next scheduled dose is within 2 days. In this situation, the patient should be directed to skip the missed dose and take the next scheduled dose on the scheduled day.

VI. Billing Code/Availability Information

HCPCS code:

- J3490 – Unclassified drugs
- C9399 – Unclassified drugs or biologicals

NDC:

- Tegsedi 284 mg/1.5 mL single-dose prefilled syringe: 72126-0007-xx

VII. References

1. Tegsedi [package insert]. Waltham, MA: Sobi, Inc., January 2024. Accessed July 2024.
2. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *N Engl J Med*. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.
3. Waddington-Cruz M, Ackermann EJ, Polydefkis M, H, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. *Amyloid*. 2018 Aug 31:1-9. doi: 10.1080/13506129.2018.1503593.
4. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8:31.
5. Sekijima Y, Nakamura K. Hereditary Transthyretin Amyloidosis. In: Adam MP, Feldman J, Mirzaa G, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. Initial Posting: November 5, 2001; Last Update: May 30, 2024. Accessed July 11, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK1194/>.
6. Luigetti M, Romano A, DiPaolantonio A, et al. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. *Ther Clin Risk Manag*. 2020; 16: 109–123. Published online 2020 Feb 21. doi: 10.2147/TCRM.S219979.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E85.1	Neuropathic hereditary amyloidosis

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC